share_log

HC Wainwright & Co. Maintains Buy on Cardiff Oncology, Raises Price Target to $14

Benzinga ·  Mar 6 19:49

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cardiff Oncology (NASDAQ:CRDF) with a Buy and raises the price target from $12 to $14.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment